Conditions: Prediabetic State
Keywords: Prediabetic State
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 3
Healthy volunteers: yes

Brief summary:
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired Glucose Tolerance (IGT), a form of prediabetes.

Detailed description:

Arms:
arm 1: Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth

\+ pioglitazone PLACEBO daily by mouth arm 2: Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth

\+ pioglitazone (TZD) 15 mg daily by mouth arm 3: Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth

\+ pioglitazone (TZD) PLACEBO daily by mouth

Interventions: intervention 1: Sitagliptin + Pioglitazone PLACEBO intervention 2: Sitagliptin + Pioglitazone intervention 3: PLACEBO
Intervention descriptions: intervention 1: Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily intervention 2: Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily intervention 3: Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily

Protocol document: